4.49
0.11 (2.51%)
| Penutupan Terdahulu | 4.38 |
| Buka | 4.24 |
| Jumlah Dagangan | 110,116 |
| Purata Dagangan (3B) | 263,300 |
| Modal Pasaran | 160,966,496 |
| Harga / Buku (P/B) | 0.400 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Mar 2025 |
| EPS Cair (TTM) | -6.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.69% |
| Nisbah Semasa (MRQ) | 12.86 |
| Aliran Tunai Operasi (OCF TTM) | -51.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.21 M |
| Pulangan Atas Aset (ROA TTM) | -25.44% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | BioAge Labs, Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.38 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 3.62% |
| % Dimiliki oleh Institusi | 66.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sands Capital Ventures, Llc | 31 Dec 2024 | 786,353 |
| Redpoint Management, Llc | 31 Dec 2024 | 383,255 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (Citigroup, 11.36%) | Pegang |
| 5.00 (Morgan Stanley, 11.36%) | Jual | |
| Median | 5.00 (11.36%) | |
| Purata | 5.00 (11.36%) | |
| Jumlah | 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 4.55 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 24 Mar 2025 | 5.00 (11.36%) | Pegang | 4.54 |
| Morgan Stanley | 07 Mar 2025 | 5.00 (11.36%) | Jual | 4.55 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Mar 2025 | Pengumuman | BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 |
| 17 Mar 2025 | Pengumuman | BioArctic receives Orphan Drug Designation for exidavnemab the US |
| 20 Feb 2025 | Pengumuman | BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference |
| 12 Feb 2025 | Pengumuman | BIOA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against BioAge Labs, Inc. (BIOA) |
| 28 Jan 2025 | Pengumuman | BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |